Inclisiran
Leqvio (inclisiran) is an oligonucleotide pharmaceutical. Inclisiran was first approved as Leqvio on 2020-12-09. It has been approved in Europe to treat dyslipidemias and hypercholesterolemia.
| Trade Name | Leqvio |
|---|---|
| Common Name | Inclisiran |
| Indication | dyslipidemias, hypercholesterolemia |
| Drug Class |
